Metoprolol for heart failure: genes and drug response
Treatments studied
Part of Heart & circulation clinical trials.
This trial tests how the drug metoprolol works in people with heart failure and reduced pumping function. It looks at whether your genetic makeup affects how the drug is processed and how well it helps your heart.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have heart failure with reduced ejection fraction (weakened heart pumping).
- You have not taken a beta-blocker (like metoprolol) in the past 3 to 6 months, or only a low dose.
- You have genetic test results already available, or are willing to give a DNA sample.
- You are white (needed for the genetic scoring).
- You are on a stable dose of certain heart medications (like ACE inhibitors or ARBs) for at least 4 weeks.
- You are not pregnant, and if you could become pregnant, you agree to use effective birth control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests tools to help doctors and patients work together to start or adjust heart failure medicines. You may qualify if your heart's pumping strength is low and you are missing certain recommended medications.
This trial tests whether a genetic test can help doctors choose the best beta blocker for people with heart failure who have mildly reduced pumping function. It aims to improve treatment by matching the drug to your genetic profile.
This study tests an experimental drug called LY3971297 to see if it can help people with chronic heart failure. It aims to find out if the drug is safe and if it improves heart function.
This study tests whether the heart medication metoprolol can help people who have both heart failure with reduced pumping function and COPD (a lung condition). It aims to see if the drug is safe and effective for this combination of conditions.
This study looks at how genes affect heart failure treatment response. It uses blood samples to find new markers that may help predict who will benefit most from therapy.
This study tests a personalized approach to safely increase the dose of your heart failure medication (beta-blocker). It aims to improve your symptoms and overall heart function by tailoring the dose to your specific needs.
Hear when a new Heart Failure With Reduced Ejection Fraction trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.